Compositions and methods for the treatment of mucositis

Patent metadata

Field	Value
Publication number	US-9840472-B2
Application number	US-201514816089-A
Country	US
Kind code	B2
Filing date	Aug 3, 2015
Priority date	Dec 7, 2013
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucositis and oral mucosal inflammatory or oral infectious diseases.

First claim

The invention claimed is:

1. A compound, wherein the compound is:

2. A compound, wherein the compound is:

3. A compound, wherein the compound is:

4. A compound, wherein the compound is:

5. A compound, wherein the compound is:

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

11. A method of treating therapeutically mucositis, ulceration of the mucous membranes lining, inflammation, hypertension, and neuropathy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 6 , and wherein said pharmaceutical composition is administered to the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, mucoadhesive administration, buccal formulation, mucoadhesive tablet, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

12. A method of therapeutically treating mucositis, ulceration of the mucous membranes lining, inflammation, hypertension, and neuropathy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 7 , and wherein said pharmaceutical composition is administered to the patient in need by oral administration, delayed release, sustained release, transmucosal, syrup, mucoadhesive administration, buccal formulation, mucoadhesive tablet, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

13. A method of therapeutically treating mucositis, ulceration of the mucous membranes lining, inflammation, hypertension, and neuropathy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 8 , and wherein said pharmaceutical composition is administered to the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, mucoadhesive administration, buccal formulation, mucoadhesive tablet, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

14. A method of therapeutically treating mucositis, ulceration of the mucous membranes lining, inflammation, hypertension, and neuropathy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 9 and wherein said pharmaceutical composition is administered to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, mucoadhesive administration, buccal formulation, mucoadhesive tablet, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

15. A method of therapeutically treating mucositis, ulceration of the mucous membranes lining, inflammation, hypertension, and neuropathy, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 10 and wherein said pharmaceutical composition is administered to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, mucoadhesive administration, buccal formulation, mucoadhesive tablet, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

Assignees

• Kandula Mahesh
• Cellix Bio Private Ltd

Inventors

• Kandula Mahesh

Classifications

• C07D233/44 Primary

  Nitrogen atoms not forming part of a nitro radical · CPC title

• C07D307/68

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title

• C07D233/50

  with carbocyclic radicals directly attached to said nitrogen atoms · CPC title

• C07C229/28

  the carbon skeleton being saturated and containing rings · CPC title

• C07C229/08

  the nitrogen atom of the amino group being further bound to hydrogen atoms · CPC title